EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate By Ogkologos - February 20, 2026 210 0 Facebook Twitter Google+ Pinterest WhatsApp New combination concerns a combination with ADT for the treatment of adult patients with mHSPC and BRCA1/2 mutations Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Middle Schooler Starts Business to Help Provide Spa and Salon Services... April 5, 2021 Advanced and Metastatic Prostate Cancer Living Guideline June 11, 2026 Lorlatinib in First-Line Treatment of Patients with Advanced ALK-Positive NSCLC With... May 30, 2022 Hugh Jackman Stops His Show To Bring Woman With Breast Cancer... August 26, 2019 Load more HOT NEWS 20 years on: how we’ve decreased cancer death rates Υποτροπιάζων ή μεταστατικός καρκίνος κεφαλής και τραχήλου: Νέα δεδομένα αναμένεται ότι... New on NCI’s Websites for June 2023 Implementation of Molecular Tumour Board Portal Developed Under the Umbrella of...
